These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 20122371

  • 1. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.
    Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y, Lanctôt KL.
    J Clin Psychiatry; 2010 Mar; 71(3):270-9. PubMed ID: 20122371
    [Abstract] [Full Text] [Related]

  • 2. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Iovieno N, Papakostas GI.
    J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
    [Abstract] [Full Text] [Related]

  • 3. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants.
    Freeman MP, Mischoulon D, Tedeschini E, Goodness T, Cohen LS, Fava M, Papakostas GI.
    J Clin Psychiatry; 2010 Jun; 71(6):682-8. PubMed ID: 20573327
    [Abstract] [Full Text] [Related]

  • 4. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
    Nelson JC.
    Depress Anxiety; 2010 Jun; 27(1):12-8. PubMed ID: 20013987
    [Abstract] [Full Text] [Related]

  • 5. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.
    Papakostas GI, Fava M.
    Eur Neuropsychopharmacol; 2009 Jan; 19(1):34-40. PubMed ID: 18823760
    [Abstract] [Full Text] [Related]

  • 6. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis.
    Iovieno N, Papakostas GI.
    J Clin Psychiatry; 2012 Oct; 73(10):1300-6. PubMed ID: 23140647
    [Abstract] [Full Text] [Related]

  • 7. Sponsorship, antidepressant dose, and outcome in major depressive disorder: meta-analysis of randomized controlled trials.
    Sinyor M, Schaffer A, Smart KA, Levitt AJ, Lanctôt KL, Grysman NH.
    J Clin Psychiatry; 2012 Feb; 73(2):e277-87. PubMed ID: 22401489
    [Abstract] [Full Text] [Related]

  • 8. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 9. Meta-analysis of placebo rates in major depressive disorder trials.
    Stolk P, Ten Berg MJ, Hemels ME, Einarson TR.
    Ann Pharmacother; 2003 Dec; 37(12):1891-9. PubMed ID: 14632596
    [Abstract] [Full Text] [Related]

  • 10. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW, Gueorguieva RV, Baker CB, Makuch RW.
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

  • 12. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
    Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW.
    Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
    [Abstract] [Full Text] [Related]

  • 13. Can people with nonsevere major depression benefit from antidepressant medication?
    Stewart JA, Deliyannides DA, Hellerstein DJ, McGrath PJ, Stewart JW.
    J Clin Psychiatry; 2012 Apr; 73(4):518-25. PubMed ID: 22226407
    [Abstract] [Full Text] [Related]

  • 14. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.
    Tedeschini E, Fava M, Papakostas GI.
    J Clin Psychiatry; 2011 Jan; 72(1):98-113. PubMed ID: 21208576
    [Abstract] [Full Text] [Related]

  • 15. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
    Henkel V, Seemüller F, Obermeier M, Adli M, Bauer M, Mundt C, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Möller HJ, Riedel M.
    J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
    [Abstract] [Full Text] [Related]

  • 16. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [Abstract] [Full Text] [Related]

  • 17. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
    Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K.
    Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
    [Abstract] [Full Text] [Related]

  • 18. Natural course and placebo response in short-term, placebo-controlled studies in major depression: a meta-analysis of published and non-published studies.
    Storosum JG, Elferink AJ, van Zwieten BJ, van den Brink W, Huyser J.
    Pharmacopsychiatry; 2004 Jan; 37(1):32-6. PubMed ID: 14750046
    [Abstract] [Full Text] [Related]

  • 19. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.
    Iovieno N, Tedeschini E, Bentley KH, Evins AE, Papakostas GI.
    J Clin Psychiatry; 2011 Aug; 72(8):1144-51. PubMed ID: 21536001
    [Abstract] [Full Text] [Related]

  • 20. Is drug-placebo difference in short-term antidepressant drug trials on unipolar major depression much greater than previously believed?
    Rihmer Z, Gonda X.
    J Affect Disord; 2008 Jun; 108(3):195-8. PubMed ID: 18280581
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.